$34.77
2.08% today
Nasdaq, Sep 16, 08:19 pm CET
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Dyne Therapeutics Inc Stock price

$34.06
-9.58 21.95% 1M
+6.29 22.65% 6M
+20.76 156.09% YTD
+24.80 267.62% 1Y
+18.16 114.21% 3Y
+10.16 42.51% 5Y
+10.16 42.51% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.99 2.99%
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Key metrics

Market capitalization $3.42b
Enterprise Value $2.67b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.40
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-271.08m
Free Cash Flow (TTM) Free Cash Flow $-220.31m
Cash position $778.84m
EPS (TTM) EPS $-3.58
P/E forward negative
Short interest 8.14%
Show more

Is Dyne Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Dyne Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Dyne Therapeutics Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Dyne Therapeutics Inc forecast:

Buy
100%

Financial data from Dyne Therapeutics Inc

Assets
Jun '24
792 792
Cash 779 779
Claims - -
Inventories - -
Other current assets Other current assets Current assets 13 13
34 34
Property, plant and equipment 32 32
Financial assets 1.93 1.93
Intangible Assets - -
Other fixed assets Other assets Fixed assets - -
Total Assets 826 826
Liabilities
Jun '24
Equity 775 775
51 51
Current liabilities 30 30
Non-current liabilities 21 21
Total Capital 826 826

In millions USD.

Don't miss a Thing! We will send you all news about Dyne Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dyne Therapeutics Inc Stock News

Neutral
GlobeNewsWire
6 days ago
NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN) on behalf of Dyne stockholders. Our investigation concerns whether Dyne has violated the federal securities laws and/or engaged in other unlawful business practices.
Neutral
Business Wire
7 days ago
NEW YORK--(BUSINESS WIRE)---- $DYN #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). The investigation concerns whether Dyne and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the i...
Negative
Investors Business Daily
13 days ago
Dyne Therapeutics stock crashed Tuesday after several key executives departed on the heels of what the company calls "unprecedented" in DMD.
More Dyne Therapeutics Inc News

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Head office United States
CEO John Cox
Employees 141
Founded 2017
Website www.dyne-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today